ReviewCancer medicine2023

Efficacy and safety of anlotinib combined with PD-1/PD-L1 inhibitors as second-line and subsequent therapy in advanced small-cell lung cancer.

Lian Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.